[
  {
    "ts": null,
    "headline": "Moderna, Novavax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official",
    "summary": "Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next head of the Department of Health and Human Services.",
    "url": "https://finnhub.io/api/news?id=328887ffeb8a0fb8d0d8423e45d2c6d4d2d04ebcca7bb79260bc090fecd04f3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731619682,
      "headline": "Moderna, Novavax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official",
      "id": 131373969,
      "image": "https://s.yimg.com/ny/api/res/1.2/NHea86qnKykuWa0XpvOD1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/c89a65b0-a2ca-11ef-b7f7-ed7acdf864ff",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next head of the Department of Health and Human Services.",
      "url": "https://finnhub.io/api/news?id=328887ffeb8a0fb8d0d8423e45d2c6d4d2d04ebcca7bb79260bc090fecd04f3e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna, Novovax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official",
    "summary": "Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next head of the Department of Health and Human Services.",
    "url": "https://finnhub.io/api/news?id=f83fed6b8745aea08f110a13595f37af5846d59987d0c29f4dfc3d52d2e8581d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731619682,
      "headline": "Moderna, Novovax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official",
      "id": 131359226,
      "image": "https://s.yimg.com/ny/api/res/1.2/NHea86qnKykuWa0XpvOD1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/c89a65b0-a2ca-11ef-b7f7-ed7acdf864ff",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next head of the Department of Health and Human Services.",
      "url": "https://finnhub.io/api/news?id=f83fed6b8745aea08f110a13595f37af5846d59987d0c29f4dfc3d52d2e8581d"
    }
  },
  {
    "ts": null,
    "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
    "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
    "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731610380,
      "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
      "id": 131357763,
      "image": "https://s.yimg.com/ny/api/res/1.2/QrvejPduXGfjO6QTtPWJsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a741676153df2123cda83c0fb107464e",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
      "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787"
    }
  },
  {
    "ts": null,
    "headline": "Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS",
    "summary": "Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS",
    "url": "https://finnhub.io/api/news?id=3c75e2d2809b157edff8c245ac6eb34f918874a2fb6faf979b5c384e02cb9d41",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731602400,
      "headline": "Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS",
      "id": 131416302,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS",
      "url": "https://finnhub.io/api/news?id=3c75e2d2809b157edff8c245ac6eb34f918874a2fb6faf979b5c384e02cb9d41"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9d487cff327bea047ff0e595cb230e1c1185eba9807d9965a3f728a542dd27f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731602340,
      "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "id": 131416303,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9d487cff327bea047ff0e595cb230e1c1185eba9807d9965a3f728a542dd27f1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : UBS Global Healthcare Conference Transcript",
    "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc at UBS Global Healthcare Conference EVENT DATE/TIME:...",
    "url": "https://finnhub.io/api/news?id=c6ae929ae8eb45d566789953d85a8db93aca5028744d4ed745b188896cf28b1f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731599286,
      "headline": "Pfizer : UBS Global Healthcare Conference Transcript",
      "id": 131357044,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc at UBS Global Healthcare Conference EVENT DATE/TIME:...",
      "url": "https://finnhub.io/api/news?id=c6ae929ae8eb45d566789953d85a8db93aca5028744d4ed745b188896cf28b1f"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth",
    "summary": "The portfolio effectively integrates the generation of dividend income with the potential for dividend growth. Read more to see my recommendations.",
    "url": "https://finnhub.io/api/news?id=94fcbbc64adccf04fc7e7a2c5d06e3b17e13f5899c88184e20788ca30ad264c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596400,
      "headline": "How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth",
      "id": 131356026,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226730172/image_1226730172.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The portfolio effectively integrates the generation of dividend income with the potential for dividend growth. Read more to see my recommendations.",
      "url": "https://finnhub.io/api/news?id=94fcbbc64adccf04fc7e7a2c5d06e3b17e13f5899c88184e20788ca30ad264c3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
    "summary": "NEW YORK, November 14, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00 a.m. GMT.",
    "url": "https://finnhub.io/api/news?id=638dd2e66cf8f0d93d382ca6eec7b55a4812eed11a0acfc952b382490219765e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596400,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
      "id": 131351758,
      "image": "https://media.zenfs.com/en/business-wire.com/b6c305a73b2d7e22f75b7cfb52b1f4f6",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, November 14, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00 a.m. GMT.",
      "url": "https://finnhub.io/api/news?id=638dd2e66cf8f0d93d382ca6eec7b55a4812eed11a0acfc952b382490219765e"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats",
    "summary": "BridgeBio Pharmaâs acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if FDA greenlights the drug.",
    "url": "https://finnhub.io/api/news?id=db0aca74265480eb2f81dba087347fd4a8276438b093bda11d276b561e6b71fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731580874,
      "headline": "BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats",
      "id": 131350535,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141713510/image_1141713510.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "BridgeBio Pharmaâs acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if FDA greenlights the drug.",
      "url": "https://finnhub.io/api/news?id=db0aca74265480eb2f81dba087347fd4a8276438b093bda11d276b561e6b71fa"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) Among The Top Dividend Contenders Right Now?",
    "summary": "We recently compiled a list of the Dividend Contenders List: Top 15. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend contenders. Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when dividends increase over […]",
    "url": "https://finnhub.io/api/news?id=2d97f1837e36713aca3477681c4fc1845ca8fce4fa55f12f91f5e33434f5bc68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731544685,
      "headline": "Is Pfizer Inc. (PFE) Among The Top Dividend Contenders Right Now?",
      "id": 131340997,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Dividend Contenders List: Top 15. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend contenders. Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when dividends increase over […]",
      "url": "https://finnhub.io/api/news?id=2d97f1837e36713aca3477681c4fc1845ca8fce4fa55f12f91f5e33434f5bc68"
    }
  },
  {
    "ts": null,
    "headline": "The Oncology Bet Is Already Paying Off For Pfizer",
    "summary": "With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.",
    "url": "https://finnhub.io/api/news?id=e84ce3a602357d20bee4b7bd007c9b71e07c6f3e65b8f8118353c95cabbf3553",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731543795,
      "headline": "The Oncology Bet Is Already Paying Off For Pfizer",
      "id": 131340999,
      "image": "https://media.zenfs.com/en/Benzinga/eeac3cc78e2352f7fe351184c2b1bf99",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.",
      "url": "https://finnhub.io/api/news?id=e84ce3a602357d20bee4b7bd007c9b71e07c6f3e65b8f8118353c95cabbf3553"
    }
  }
]